Aimmune announces publication of AR101 peanut allergy treatment data
Aimmune Therapeutics announced that its investigational treatment for peanut allergy, AR101, was highlighted in a recent publication by Benaroya Research Institute at Virginia Mason focused on the discovery of an immune cell subset, TH2A cells, that appears to be involved in the pathogenesis of allergies. These allergen-specific T cells are present in people with allergies but nearly entirely absent from people without allergies. The publication, which appeared in the August 2 issue of Science Translational Medicine, also reported that, in a small pilot experiment, AR101 treatment was associated with a significant reduction of TH2A cells in blood samples from a subset of peanut-allergic patients from Aimmune's ARC001 trial. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Benaroya Research Institute's work with the Aimmune samples potentially represents a new way to measure the allergy process and assess the effectiveness of specific treatments. In addition to the work on peanut allergy, the published article, "A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders," also reported on tests of allergies to grass and tree pollens, cat dander, dust mites, and mold, where TH2A played a pivotal role as well. The researchers found that these TH2A cells associated with stable allergic disease are terminally differentiated CD4+ T cells that exhibit several functional attributes that distinguish them from conventional TH2 cells.